# US 2023/0067480 A1 · Method for treating usher syndrome and composition thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067480 A1
- Document ID: US20230067480A1
- Status: Published application
- Kind: A1
- Application number: 17/790,484
- Filed: 2020-12-30
- Published: 2023-03-02
- Earliest claimed: 2019-12-30
- Assignees: Edigene Therapeutics (Beijing) Inc.
- Applicants: EDIGENE THERAPEUTICS (Beijing) INC.
- Inventors: Nengyin LIU; Zexuan YI; Pengfei YUAN; Yanxia ZHAO; Gangbin TANG
- Web page: https://patentgrep.com/patent/US20230067480A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14141: Use of virus, viral particle or viral elements as a vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a method for targeted editing of target RNA containing a G to A mutation in a USH2A gene transcript based on LEAPER technology, comprising: introducing a construct of an adenosine deaminase recruiting RNA (arRNA) for editing the target RNA or a construct encoding said arRNA into a cell, wherein the arRNA comprises a complementary RNA sequence that hybridizes to the target RNA, and wherein the arRNA is capable of recruiting adenosine deaminase acting on RNA (ADAR), so that the target adenosine in the target RNA is deaminated, thereby performing in vivo editing of the base from A to I on RNA safely and effectively, repairing a pathogenic mutation site, and achieving the purpose of treating disease such as Usher syndrome.

## Claims

### Claim 1

A method for targeted editing of target RNA in a cell based on LEAPER technology, wherein the target RNA is an RNA containing a G to A mutation in a USH2A gene transcript, comprising:
introducing a construct comprising an adenosine deaminase recruiting RNA (arRNA) for editing the target RNA or a construct encoding the arRNA into the cell, wherein the arRNA comprises a complementary RNA sequence that hybridizes to the target RNA, and wherein the arRNA is capable of recruiting adenosine deaminase acting on RNA (ADAR), thereby the target adenosine in the target RNA is deaminated.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the target RNA is a pre-mRNA.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, wherein the length of the arRNA is about 151-61 nt, 131-66 nt, 121-66 nt, 111-66 nt, 91-66 nt, or 81-66 nt.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the length of the arRNA is any natural number selected from 66 nt-131 nt.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1-4, wherein the length from the targeting base to the 3′ end in the arRNA is ≥7 nt, ≥10 nt, ≥15 nt, preferably 16-55 nt, 20-50 nt, 25-45 nt, 25-35 nt, or 25-30 nt.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1-5, wherein the length from the targeting base to the 5′ end in the arRNA is ≥25 nt, ≥30, ≥35, ≥45, preferably 46-90 nt, 50-85 nt, 55-80 nt, 60-75 nt, or 65-70 nt.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein a targeting base is introduced into the arRNA to pair with the target A in the target sequence, and the preference order of the targeting base from high to low is C, A, U, or G.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method according to any one of claims 1-7, wherein the target RNA is an RNA comprising a transcribed human USH2A gene NM_206933.2(USH2A)_c.11864 G>A (p.Trp3955Ter) mutation site.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1-8, wherein the arRNA is selected from the group consisting of: SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to any one of claims 1-9, wherein the arRNA is selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method according to any one of claims 1-10, wherein the construct is a linear nucleic acid, a viral vector, or a plasmid.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the viral vector is an adeno-associated virus (AAV) vector or a lentiviral vector.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the AAV vector is introduced into the cell by infection after being packaged into an AAV2, AAV5 or AAV8 capsid.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the AAV vector is introduced into the cell by infection after being packaged into an AAV8 capsid.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1-14, wherein the cell is an optic nerve cell or auditory nerve cell of a mammalian.

### Claim 16

An arRNA for targeted editing of the target RNA containing a G to A mutation in a USH2A gene transcript, comprising or consisting of a sequence selected from the group consisting of: SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

### Claim 17 (depends on 16)

A construct or delivery vector comprising the arRNA according to claim 16.

### Claim 18 (depends on 17)

The construct or delivery vector according to claim 17, which is a plasmid, virus, liposome, or lipid nanoparticle.

### Claim 19 (depends on 18)

The construct or delivery vector according to claim 18, which is an adeno-associated virus (AAV) or a lentivirus.

### Claim 20 (depends on 19)

The construct or delivery vector according to claim 19, wherein the virus is AAV2, AAV5, or AAV8.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A cell obtained by the editing method according to any one of claims 1-15.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method for treating Usher type II syndrome in an individual, comprising correcting a G to A mutation associated with Usher type II syndrome in a cell of the individual by the method according to any one of claims 1-15.

### Claim 23 (depends on 16, 17, 18, 19, 20, 22)

The method according to claim 22, comprising introducing the arRNA according to claim 16 or the construct or delivery vector according to any one of claims 17-20 into a subject.

### Claim 24 (depends on 16, 17, 18, 19, 20, 23)

The method according to claim 23, wherein the arRNA according to claim 16 or the construct or delivery vector according to any one of claims 17-20 is introduced into the subretinal space of the subject.

### Claim 25 (depends on 16, 17, 18, 19, 20)

Use of the arRNA according to claim 16 or the construct or delivery vector according to any one of claims 17-20 in the preparation of a medicament for treating Usher type II syndrome.
